Homologous recombination deficiency real-time clinical assays, ready or not?-Reference-Cited by-同舟云学术

Homologous recombination deficiency real-time clinical assays, ready or not?

Published:2020-12 Issue:3 Volume:159 Page:877-886
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Fuh Katherine,Mullen Mary,Blachut Barbara,Stover Elizabeth,Konstantinopoulos Panagiotis,Liu Joyce,Matulonis Ursula,Khabele Dineo,Mosammaparast Nima,Vindigni Alessandro

Funder

Merck

Eisai

Publisher

Elsevier BV

Subject

Obstetrics and Gynaecology,Oncology

Reference71 articles.

1. Endogenous DNA double-strand breaks: production, fidelity of repair, and induction of cancer;Vilenchik;Proc. Natl. Acad. Sci. U. S. A.,2003

2. Spatiotemporal dynamics of homologous recombination repair at single collapsed replication forks;Whelan;Nat. Commun.,2018

3. Defining and modulating ‘BRCAness’;Byrum;Trends Cell Biol.,2019

4. Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer;Konstantinopoulos;Cancer Discov.,2015

5. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing;Walsh;Proc. Natl. Acad. Sci. U. S. A.,2011

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current HRD assays in ovarian cancer: differences, pitfalls, limitations, and novel approaches;Frontiers in Oncology;2024-08-16

2. Harmonization of homologous recombination deficiency testing in ovarian cancer: Results from the MITO16A/MaNGO-OV2 trial;European Journal of Cancer;2024-07

3. BRCA1 foci test as a predictive biomarker of olaparib response in ovarian cancer patient-derived xenograft models;Frontiers in Pharmacology;2024-06-25

4. Homologous recombination proficient subtypes of high-grade serous ovarian cancer: treatment options for a poor prognosis group;Frontiers in Oncology;2024-06-04

5. Poly(ADP-Ribose) Polymerase Inhibitor Development: Promising Strategies to Move Beyond Approved Indications;JCO Precision Oncology;2024-06